SKLB06329
SKLB06329 is a potent selective Type I PRMTs inhibitor. SKLB06329 shows good selectivity for PRMT6 (IC50 = 3.86 nM) over Type II/III PRMTs (PRMT5/7) and shows no significant inhibition against various lysine methyltransferases (PKMTs) . SKLB06329 significantly inhibits the proliferation of triple-negative breast cancer (TNBC) cells, induces apoptosis, and suppresses the expression of asymmetric dimethylarginine (ADMA) within cells. SKLB06329 can be used for triple-negative breast cancer research[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; Histone Methyltransferase
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
CN(CC1=NNC2=CC=C(C=C21)C3=CC=C(C=C3)NS(=O)(C4CC4)=O)CCN
Molecular Formula
C20H25N5O2S
Molecular Weight
399.51
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PRMT6
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Anti-Human CTGF/CCN2 Antibody (SAA0452), PerCP
Lentiviral human C6orf132 shRNA (UAS) - Lentiviral human C6orf132 shRNA (UAS, iRFP) plasmid
Recombinant Rat Regulator of G-protein signaling 18 (Rgs18)